Adults aged 50–59 years who have medical conditions that increase their risk of severe RSV disease can consider RSV vaccination
Adults aged 50–59 years who have a risk factor for severe RSV disease can consider a single dose of Arexvy. See Table. Conditions associated with increased risk of severe RSV disease in adults.
Arexvy is the only vaccine registered for use in people aged 50-59 years with medical conditions that increase their risk of severe disease.
RSV vaccine may be given at any time of the year but, where possible, should be offered before the start of the RSV season, which typically occurs from April to September. Adults recommended to receive an RSV vaccine, who have previously had an RSV infection, can receive it once they are recovered.
Protection lasts for at least 2 years. Recommendations on revaccination will be updated when data become available.
Adults aged ≥50 years with the medical conditions listed below are at increased risk of severe RSV disease. These examples are not exhaustive, and providers may include people with conditions similar to those listed below based on clinical judgement.
| Risk category | Example medical condition |
|---|---|
| Cardiac disease |
|
| Chronic respiratory conditions |
|
| Immunocompromising conditions |
|
| Chronic metabolic disorders |
|
| Chronic kidney disease |
|
| Chronic neurological conditions |
|
| Chronic liver disease |
|
| Obesity |
|